On February 6, 2023 Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") reported that at the meeting of the Board of Directors held today, a resolution was adopted to acquire its own shares pursuant to the provision of its Articles of Incorporation in accordance with Article 459, paragraph 1 of the Companies Act (Press release, Astellas, FEB 6, 2023, View Source [SID1234626858]). The Company also announced that it decided to cancel its treasury stock pursuant to the provisions of Article 178 of the Companies Act. The details are as follows.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Reasons for the acquisition of own shares
To improve capital efficiency and shareholder return.

Details of the acquisition of own shares
(1) Class of shares to be acquired:　　Common stock of the Company
(2) Total number of shares to be acquired:　　Up to 29 million shares
　　　　　　(Ratio to the total number of shares outstanding [excluding treasury stock]: 1.59%)
(3) Total amount of acquisition cost:　　Up to 50 billion yen
(4) Period of acquisition:　　From February 7, 2023 to March 24 ,2023
(5) Method of acquisition:　　Marked purchase on the Tokyo Stock Exchange

Details of the cancellation of treasury stock
(1) Class of shares to be cancelled:　　Common stock of the Company
(2) Number of shares to be cancelled:　　All of the shares acquired as stated in 2 above
(3) Cancellation date:　　March 29, 2023 (planned)
＊ The actual number of shares to be cancelled will be announced after
completing the acquisition of own shares stated in 2 above.
(Reference) Status of treasury stock as of December 31, 2022:

Total number of shares outstanding (excluding treasury stock): 1,822,806,495 shares
Total number of treasury stocks: 13,045,080 shares

On February 6, 2023 Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, reported that management will participate in three upcoming investor conferences (Press release, Arvinas, FEB 6, 2023, View Source [SID1234626857]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Guggenheim Oncology Conference on Thursday, February 9. Ron Peck, M.D., Chief Medical Officer, and Sean Cassidy, Chief Financial Officer, will participate in a fireside chat. A live audio webcast of the presentation will be available here and on the Events + Presentations section of the Company’s website.

SVB Leerink Global Healthcare Conference on Thursday, February 16. Ron Peck, M.D., Chief Medical Officer, and Randy Teel, Ph.D., Senior Vice President, Corporate and Business Development, will participate in a fireside chat. A live audio webcast of the presentation will be available here and on the Events + Presentations section of the Company’s website.

Citi Oncology Leadership Summit on Thursday, February 23. Ian Taylor, Ph.D., Chief Scientific Officer, will participate in a fireside chat. A live audio webcast of the presentation will be available here and on the Events + Presentations section of the Company’s website.

On February 6, 2023 Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target specific viral diseases, reported that the Arbutus management team will participate in and host one-on-one meetings at the following three upcoming investor conferences (Press release, Arbutus Biopharma, FEB 6, 2023, View Source [SID1234626856]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

SVB Securities Global Biopharma Conference – Virtual: February 14-16, 2023

Cowen 43rd Annual Health Care Conference: Formal Presentation at 1:30 pm ET on March 7, 2023

Jefferies Biotech on the Bay Summit: March 16-17, 2023

To access the live webcast of the presentation for the Cowen 43rd Annual Health Care Conference please visit: View Source An archived replay of the webcast will be available on the Arbutus website for a limited time after the event.

On February 6, 2023 Akoya Biosciences, Inc. (Nasdaq: AKYA) ("Akoya"), The Spatial Biology Company, reported that it will release financial results for the fourth quarter and full year of 2022 after the market close on Monday, March 6th, 2023 (Press release, Akoya Biosciences, FEB 6, 2023, View Source [SID1234626855]). Company management will host a conference call to discuss financial results at 5:00 p.m. ET.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Investors interested in listening to the conference call are required to register online. It is recommended to register at least a day in advance. A live and archived webcast of the event will be available on the "Investors" section of the Akoya website at View Source

Akoya also announced that Brian McKelligon, CEO, will be participating in two upcoming investor conferences.

BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference

43rd Annual Cowen Healthcare Conference
Tuesday, March 7th at 2:10 p.m. ET
A live webcast of the 43rd Annual Cowen Healthcare Conference will be available on the "Investors" section of the Akoya website View Source

On February 6, 2023 Aim Immunotech presented its investor presentation (Presentation, AIM ImmunoTech, FEB 6, 2023, View Source [SID1234626854]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!